Trials / Terminated
TerminatedNCT02375685
Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Institut de Recherches Internationales Servier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate long-term safety of gevokizumab in patient with chronic non-infectious uveitis who previously well tolerated the study drug and may benefit from longterm treatment with gevokizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Gevokizumab |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2015-03-03
- Last updated
- 2020-01-03
Locations
13 sites across 13 countries: Australia, Austria, France, Germany, Greece, Italy, Portugal, South Korea, Spain, Taiwan, Tunisia, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02375685. Inclusion in this directory is not an endorsement.